Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome

The 25-week weight loss study which achieved its previously reported primary endpoints also examined the effects of GS200 on insulin resistance Gelesis Holdings Inc. (NYSE:GLS) ("Gelesis" or the "Company") the maker of Plenity for weight management,